Qiagen (NYSE:QGEN) and Adverum Biotechnologies (NASDAQ:ADVM) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation.
Risk & Volatility
Qiagen has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 3.82, meaning that its stock price is 282% more volatile than the S&P 500.
This table compares Qiagen and Adverum Biotechnologies’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
This is a breakdown of current ratings and price targets for Qiagen and Adverum Biotechnologies, as provided by MarketBeat.com.
||Strong Buy Ratings
Qiagen presently has a consensus target price of $40.60, suggesting a potential upside of 12.81%. Adverum Biotechnologies has a consensus target price of $10.75, suggesting a potential upside of 137.31%. Given Adverum Biotechnologies’ stronger consensus rating and higher possible upside, analysts plainly believe Adverum Biotechnologies is more favorable than Qiagen.
Earnings and Valuation
This table compares Qiagen and Adverum Biotechnologies’ gross revenue, earnings per share and valuation.
||Earnings Per Share
Qiagen has higher revenue and earnings than Adverum Biotechnologies. Adverum Biotechnologies is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
65.2% of Qiagen shares are held by institutional investors. Comparatively, 58.4% of Adverum Biotechnologies shares are held by institutional investors. 9.0% of Qiagen shares are held by insiders. Comparatively, 5.0% of Adverum Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Qiagen beats Adverum Biotechnologies on 10 of the 14 factors compared between the two stocks.
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions. It also provides Ingenuity Variant Analysis, a cloud-based platform that interprets data from next-generation sequencing (NGS) analysis; QIAGEN Clinical Insight, an evidence-based decision support solution; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web-based portal that enables researchers to search and select gene-and pathway-specific solutions from pre-designed and custom PCR assay kits, NGS assay panels, and other products. In addition, the company offers instrumentation systems for laboratories. Its automation platforms include QIAsymphony, a modular system; GeneReader NGS System, a sample to insight NGS solution for laboratories to deliver actionable results; QIAcube robotic workstations, which provides versatile solutions for automated sample processing; QIAxcel for nucleic acid separation; QIAgility, a benchtop instrument for PCR setup; and ESEQuant instruments that enable optical measurement for point of need molecular testing in physician practices, emergency rooms, remote areas, and other applications. It serves molecular diagnostics, applied testing, pharma, and academia customers. QIAGEN N.V. has a collaboration with Bristol-Myers Squibb to develop gene expression profiles for immuno-oncology therapies. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
About Adverum Biotechnologies
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates that target serious rare and ocular diseases. It leverages its adeno-associated virus (AAV)-based directed evolution platform to develop products. The company's pipeline of product candidates include ADVM-043 to treat alpha-1 antitrypsin deficiency, which is in Phase I/II clinical trial; and ADVM-053 for hereditary angioedema disease, which is in preclinical stage; as well as ADVM-022 and ADVM-032 for wet age-related macular degeneration disease, which are in preclinical stage. It has collaboration agreement with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets, as well as includes AVA-311 for the treatment of juvenile X-Linked Retinoschisis. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.